Ibnsina Pharma results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements.
Net profit39.62 millionEGP · −25.2% vs the same period a year earlier
Total assets18.55 billionEGP · +44.2% vs the same period a year earlier
Shareholders' equity1.45 billionEGP · +15.0% vs the same period a year earlier
Operating cash flow536 millionEGP · −12.7% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q4 2023 was about 39.62 million EGP, down −25.2% from 52.99 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 18.55 billion EGP, and shareholders' equity about 1.45 billion EGP.
- Operating cash flow for Q4 2023 was positive at 536 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit39.62 million52.99 million−25.2%
Gross profit688 million419 million+64.1%
Total assets18.55 billion12.86 billion+44.2%
Total liabilities17.1 billion11.6 billion+47.4%
Shareholders' equity1.45 billion1.26 billion+15.0%
Total liabilities and equity18.55 billion12.86 billion+44.2%
Operating cash flow536 million614 million−12.7%
Investing cash flow-13.27 million-15.61 million+15.0%
Financing cash flow-116 million-533 million+78.2%
Net change in cash406 million65.39 million+521.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy